Marquette University
Press Release

Marquette University President Michael R. Lovell to attend White House welcome ceremony for Pope Francis

Francis, who was named pope on March 13, 2013, is the first Jesuit pope.

By - Sep 15th, 2015 02:38 pm

MILWAUKEE – Marquette University President Michael R. Lovell will attend the welcome ceremony for Pope Francis at the White House on Wednesday, Sept. 23.

President Lovell will be available to speak to the media about this special honor on Friday, Sept. 18, from 1:30 p.m. to 2:30 p.m. at St. Joan of Arc Chapel on Marquette’s campus. He often has spoken of how his faith affects his leadership role at Marquette.

When Lovell was first elected as the 24th and first lay president of Marquette University, he said: “As a devout Catholic, my faith has always served as the cornerstone of my life. Having the ability to openly share my faith in my professional career is something that I have always wanted to do.”

Marquette is one of 28 Catholic and Jesuit universities and colleges in the United States. Francis, who was named pope on March 13, 2013, is the first Jesuit pope.

Pope Francis, who is just the third pope to visit the White House, will arrive in Washington D.C. for a State Arrival Ceremony. The event will be held on the South Lawn of the White House with President Barack Obama and numerous other government officials in attendance.

Mentioned in This Press Release

Organizations:

Recent Press Releases by Marquette University

Marquette University

Children’s Hospital president and CEO Troy goes ‘On the Issues’ at Marquette Law School

Troy leads a billion-dollar health system that is dedicated to children and employs nearly 5,000 people throughout the state.

Marquette University

Political consultant Pudner goes ‘On the Issues’ at Marquette Law School

Pudner has managed political campaigns for almost three decades.

Marquette University

Company founded by two Marquette University researchers raises $26 million in funding

The investment will finance key clinical trials of the company’s most promising compound targeting neuropsychiatric disorders.

Leave a Reply

Your email address will not be published. Required fields are marked *